Schwere Thrombozytopenie unter Valproattherapie

Heuberger, A.; Dempfle, Carl-Erik; Teich, M.; Koelfen, W.; König, S. A.

doi:10.1007/s00112-001-0350-6

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These complications did not receive much attention in literature, because they are usually harmless, clinically not relevant, and, therefore, do rarely lead to the necessity of discontinuation of VPA treatment [8,9]. In a recent review of the literature, Heuberger et al [8] only found 37 cases of clinically relevant thrombocytopenia in patients treated with VPA. The platelet count ranges between 5,000 and 80,000/Ìl in these cases, and discontinuation of VPA treatment was the measure of choice in almost all of these patients [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Valproic-Acid-Induced Thrombocytopenia and Hepatotoxicity: Discontinuation of Treatment?

Lackmann¹

2004

Pharmacology

View full text Add to dashboard Cite

We report the case of a 4-year-old boy with long-term sodium valproate (valproic acid; VPA) therapy who suddenly developed clinically relevant thrombocytopenia and signs of hepatotoxicity. Reduction of the VPA dosage led to clinical and laboratory parameter improvement, while discontinuation of therapy was not necessary. The current practice of the management of VPA-induced side effects is discussed in view of the current recommendations from the literature.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In a recent review of the literature, Heuberger et al [8] only found 37 cases of clinically relevant thrombocytopenia in patients treated with VPA. The platelet count ranges between 5,000 and 80,000/Ìl in these cases, and discontinuation of VPA treatment was the measure of choice in almost all of these patients [8].…”

Section: Introductionmentioning

confidence: 99%